Nemolizumab for adults with scleroderma
Treatments studied
Part of Lungs & breathing, Skin clinical trials.
This study tests an investigational drug called nemolizumab for adults with systemic sclerosis (scleroderma). It aims to see if the drug can help reduce skin thickening and other symptoms, especially in people with early or moderate disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of systemic sclerosis (scleroderma).
- Your skin thickening must be moderate (score between 12 and 30 if you have diffuse type, or 8 or more if limited type, and you must not have anti-centromere antibodies if limited).
- Your disease must be early (within 5 years for diffuse, or 2 years for limited).
- You may be on stable doses of methotrexate, mycophenolate, or nintedanib for at least 3 months.
- You cannot have certain other autoimmune diseases, severe organ damage, or recent infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This Phase 2 study tests whether combining belimumab and rituximab can improve skin thickening in people with early diffuse cutaneous systemic sclerosis (dcSSc). It may help slow the disease process and improve skin symptoms, but it also requires screening for immune and infection risks.
This study tests if a new drug called nemolizumab can help reduce itch in women with lichen sclerosus (LS) in the genital area. Participants must have tried topical steroids before.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This study tests a new injected medication called nemolizumab for people with moderate-to-severe eczema (atopic dermatitis) that hasn't been controlled by creams or ointments. The goal is to see if it reduces symptoms like itching and skin inflammation better than a placebo (inactive shot).
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.